RxDoctor Payments Data

Kirby Stacks, NP

Family · Seymour, INNPI 1841606951

Payments from drug & device makers

$4,284in general payments, 2019–2025

Across 256 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$935
  • Lilly USA, LLC$756
  • AstraZeneca$403
  • GSK$343
  • Novartis$239
  • Novo Nordisk$185
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$4,26199%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,284 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$4,100
Medicare patients
100
Services billed
224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide47$51,245
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$44,229
EliquisApixaban39$30,734
XareltoRivaroxaban12$8,650
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$7,676
SymbicortBudesonide/Formoterol Fumarate15$3,447
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,219
Albuterol Sulfate HfaAlbuterol Sulfate61$1,425
Omeprazole112$1,075
Cefdinir69$938
Levothyroxine Sodium118$935
SynthroidLevothyroxine Sodium22$910
Atorvastatin Calcium102$881
Losartan Potassium100$841
Duloxetine Hcl45$768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$343$51,90565 claims
Lilly USA, LLCTrulicity$756$51,24547 claims
PfizerEliquis$180$30,73439 claims
AstraZenecaSymbicort$403$3,44715 claims
AbbVieSynthroid$935$91022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.

Other family in Seymour

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →